| Vaccine Only (n=30) | Vaccine + GM-CSF (n=30) | p-Value | |
|---|---|---|---|
| Mean Age ± SD (in years) | 38.5 ± 10.0 | 37.3 ± 9.7 | 0.619 |
| Race | |||
| AA | 23 (76.7%) | 20 (66.7%) | 0.390 |
| Caucasian | 7 (23.3%) | 10 (33.3%) | |
| Gender | |||
| Female | 17 (56.7%) | 18 (60%) | 0.793 |
| Male | 13 (43.3%) | 12 (40%) | |
| Mean BMI ± SD | 29.3 ± 7.6 | 30.3 ± 11.1 | 0.691 |
| Current smoker | 11 (36.7%) | 10 (33.3%) | 0.787 |
| Reactive HCV Ab | 2 (6.7%) | 1 (3.3%) | 0.554 |
| Mean log10 plasma HIV RNA ± SD | 2.7 ± 1.1 | 3.0 ± 1.2 | 0.455 |
| Plasma HIV RNA | 16 (53.3%) | 16 (53.3%) | 1.0 |
| < 400 copies/mL | |||
| Median Nadir CD4 count (IQR) | 162 (71-271) | 207 (91-304) | 0.429 |
| Median CD4 count at enrollment (IQR) | 375.5 (290-663) | 425 (288-564) | 0.865 |
| On ART at enrollment | 21 (70%) | 21 (70%) | 1.0 |